



2024
APPLE

**THE 14TH ASIA-PACIFIC
PRIMARY LIVER CANCER EXPERT MEETING**

Novel Insights into the Evolution of Liver Cancer Management

JULY 18–20, 2024



INTRODUCTION

Welcome Message	3
Organizing Committee	4

GENERAL INFORMATION

General Information	5
Accredited Continuing Education (CE) Information	6
Acknowledgement of Educational Grant Support	6
Conference Site Map	7

FACULTY

Faculty List	8
Disclosures	9

PROGRAM AT A GLANCE

Friday, July 19, 2024	12
Saturday, July 20, 2024	14

AGENDA

Friday, July 19, 2024	15
Saturday, July 20, 2024	17

CE-CERTIFIED SATELLITE SYMPOSIUM

Medical Crossfire®: Individualizing Treatment Plans in Advanced Hepatocellular Carcinoma Based on Biology and Other Patient Characteristics	19
---	----

Exhibit Hall Map and Exhibitor List	20
Poster Hall & Directory	21

WELCOME MESSAGE

Dear Colleagues and Friends,

On behalf of the organizing committee of the 14th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2024), we would like to welcome you to the annual conference, which will be held on July 18–20, 2024, at the Sheraton Waikiki in Honolulu, Hawaii.

Following the great success of the previous APPLE meetings hosted in various countries in Asia, we are excited to bring this meeting to the United States for the first time ever. It is our hope that this meeting will serve as an important platform for sharing valuable research for the treatment of liver cancer. APPLE 2024 will focus on fostering and promoting intellectual collaboration and exchange between physicians, scientists, and industry leaders across the globe, facilitating innovation in liver cancer treatment.

We will provide all the participants with an excellent opportunity to engage in a dialogue with distinguished scholars and experts as well as industry leaders so they can play a crucial role in developing solutions to the most pressing issues in liver cancer, generating consensus on various perspectives of its treatment that will build a brighter today and tomorrow in our profession.

Thank you.



Ghassan Abou-Alfa, MD, MBA
Hosting Chairperson
APPLE 2024



Linda L. Wong, MD
Hosting Chairperson
APPLE 2024



Norihiro Kokudo, MD, PhD, FACS
President
The APPLE Association

ORGANIZING COMMITTEE

GOVERNING BOARD OF THE APPLE ASSOCIATION

President
Norihiro Kokudo (Tokyo)
Secretary General
Chih-Hung Hsu (Taipei)
Vice Secretary General
Do Young Kim (Seoul)
Treasurer and President-Elect
Jian Zhou (Shanghai)
Scientific Committee Co-Chairs
Masafumi Ikeda (Kashiwa)
Irene Ng (Hong Kong)
Publication Co-Chairs
Michiie Sakamoto (Tokyo)
Kyung-Suk Suh (Seoul)
Education Committee Co-Chairs
Pierce Chow (Singapore)
Chiun Hsu (Taipei)
Advisory Board Members
Ann-Lii Cheng (Taipei)
Kwang-Hyub Han (Seoul)
Masatoshi Kudo (Osaka)
Jinsil Seong (Seoul)
Sheng-Long Ye (Shanghai)

Council
Ghassan Abou-Alfa (New York)
Tan To Cheung (Hong Kong)
Kiyoshi Hasegawa (Tokyo)
Naomi Khaing Than Hlaing (Yangon)
Yi-Hsiang Huang (Taipei)
Yoon Jun Kim (Seoul)
Masayuki Kurosaki (Tokyo)
Young Nyun Park (Seoul)
Hyunchul Rhim (Seoul)
Ying-Hong Shi (Shanghai)
Linda Wong (Honolulu)
Kengo Yoshimitsu (Fukuoka)
Zhao-Chong Zeng (Shanghai)
Andrew Zhu (Shanghai/Massachusetts)
Yinghua Zou (Beijing)

GENERAL INFORMATION

The 14th Asia-Pacific Primary Liver Cancer Expert Meeting

Date: July 18 – 20, 2024

Venue: Sheraton Waikiki in Honolulu,
Hawaii, USA

Official Language: English

Hosted by: Physicians Education Resource®

Registration Desk

Location: Hawaii Ballroom Foyer

Open: Friday, July 19 from 6:30 AM – 5:30 PM, and
Saturday, July 20, from 6:30 AM – 5:30 PM

Participants will receive their name badges when
collecting their meeting materials onsite. Participants are
required to wear their name badges during all meeting
events.

Meals

Breakfast (All Participants):

July 19, 7:00 AM – 8:00 AM

July 20, 7:15 AM – 8:15 AM

Lunch (All Participants):

July 19, 12:55 PM – 2:10 PM

July 20, 12:40 PM – 1:55 PM

Offsite Faculty Dinner (Invitation Only):

July 18, 5:30 PM – 8:30 PM

Welcome Luau Dinner (All Participants):

July 19, 6:30 PM – 8:30 PM

Guests are welcome to attend the Gala Dinner. There is a
small fee associated with this. Please visit the registration
desk to register your guest for the Gala Dinner.

Opening Ceremony

Location: Hawaii Ballroom: Kauai & Maui

Date & Time:

Friday, July 19, 8:15 AM – 8:35 AM

Closing Ceremony

Location: Hawaii Ballroom: Kauai & Maui

Date & Time:

Saturday, July 20, 5:05 PM – 5:30 PM

Poster Presentation

Location: Exhibit Hall Located in Hawaii Ballroom: Lanai

Date and Time:

Friday, July 19,

10:45 AM – 11:15 AM and 2:10 PM – 2:40 PM

Saturday, July 20,

10:00 AM – 10:30 AM and 1:55 PM – 2:25 PM

Exhibit Hall

Location: Lana'i Room

Date and Time:

July 19, 7:15 AM – 5:30 PM

July 20, 7:15 AM – 5:30 PM

Alcohol Policy

We recognize the legitimate serving of alcoholic
beverages in the process of conducting business and
social activities. We also recognize that the use and
consumption of alcohol carries with it the requirement for
all attendees to consume those beverages responsibly
and in keeping with our professional code of ethics and
conduct. We strongly oppose the abuse and misuse of
alcohol.

Americans With Disabilities Act

We take pride in ensuring that our events and functions
are accessible to all attendees with special needs. All
meeting rooms are wheelchair accessible. If you require
special arrangements, please contact our staff at the
Registration Desk.

Interactive Audience Response System

We encourage you to actively participate in the
discussion throughout the day by answering questions
during each session. In order to participate, please follow
the instructions below to log on to our polling system. All
responses are confidential.


WiFi Information:

Network: **MarriottBonvoy_Conference**

Password: **APPLE2024**

Network Log-In Instructions:

- Enter your Password into the Welcome
Page
- If the Welcome Page doesn't appear
shortly, direct your browser to a
popular website to launch the page



Log on to: www.gotoper.com/apple24-engage

Once you log into the platform, you will be able to:

- Follow along with the presentations in real-time, save
slides, and take notes
- Submit questions for the faculty to address during Q&A
- Respond to live polling questions and view the results
- Provide feedback on the content and presenters

GENERAL INFORMATION *(Continued)*

Personal Accountability Commitment

Physicians' Education Resource®, LLC's (PER®'s) top priority is the safety and security of our attendees, faculty, exhibitors, staff, and operational personnel. As we develop the programming for this activity, PER® is working diligently to implement health and safety protocols based on the advice of health experts and the latest guidelines and local regulations to optimize health and safety conditions for attendees during the event. Please note that attendance at any public event increases the risk of contracting a communicable illness. Attendees assume all risk associated with attendance. Any attendees who feel ill, regardless of their symptoms, should not attend this event.

Target Audience

This educational activity is directed toward physicians involved in the diagnosis, treatment and management of liver cancer. Other health care professionals interested in the treatment of these malignancies are also invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

- Explain the diagnostic criteria and critical molecular biomarkers to identify HCC and BTC and assist in treatment decision-making for patients with these tumors
- Determine the mechanistic rationale behind novel therapies under clinical investigation for the treatment of patients with HCC and BTC
- Assess recent clinical evidence from studies evaluating current and emerging therapies for the management of patients with liver cancers including HCC and BTC
- Integrate potentially practice-changing safety and efficacy evidence into individualized care plans for patients with HCC and BTC

Slides/e-Syllabus

Final slides will be uploaded to the e-syllabus on the PER website by 12:00 PM US EDT on Monday, July 22, 2024.

To access these materials, please visit

<https://gotoper.com/asia-pacific-primary-liver-cancer-expert-meeting-esyll>

How to Request Credit

To complete the online evaluation and receive a certificate of credit or participation, please visit <https://www.gotoper.com/asia-pacific-primary-liver-cancer-expertmeeting-eval>

The online evaluation and the request for credit will be available beginning Sunday, July 21, 2024 and will remain available until Wednesday, September 4, 2024.

Accreditation/Designation of Credit

Physicians' Education Resource, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource, LLC designates this live activity for a maximum of 15.0 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Physicians' Education Resource, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 15.0 Contact Hours.

Acknowledgement of Educational Grant Support

This activity is supported by educational grants from Incyte Corporation and Taiho Oncology, Inc.

CONFERENCE MAP

2ND FLOOR



FACULTY

Asia

Albert Chan	<i>Albert Chan The University of Hong Kong</i>
Stephen Chan	<i>The Chinese University of Hong Kong</i>
Ann-Lii Cheng	<i>National Taiwan University Cancer Center</i>
Tan To Cheung	<i>The University of Hong Kong</i>
Valerie Chew	<i>Duke-NUS Medical School</i>
Kwang-Hyub Han	<i>Han CHA medical center</i>
Etsuro Hatano	<i>Kyoto University</i>
Yi-Hsiang Huang	<i>National Yang Ming Chio Tung University</i>
Chih-Hung Hsu	<i>National Taiwan University Hospital</i>
Masafumi Ikeda	<i>National Cancer Center Hospital East</i>
Haeryoung Kim	<i>Seoul National University College of Medicine</i>
Hyo-Cheol Kim	<i>Seoul National University Hospital</i>
Takahiro Kodama	<i>Osaka University</i>
Norihiro Kokudo	<i>National Center for Global Health and Medicine</i>
Ming Kuang	<i>The First Affiliated Hospital, Sun Yat-sen University</i>
Masatoshi Kudo	<i>Kindai University</i>
Masayuki Kurosaki	<i>Musashino Red Cross Hospital</i>
Jeong Min Lee	<i>Seoul National University Hospital</i>
Xiao Li	<i>Xiamen University, Department of Oncology, Zhongshan Hospital of Xiamen University</i>
Lian-Xin Liu	<i>The First Affiliated Hospital of USTC</i>
Yasunori Minami	<i>Osaka University</i>
Irene Ng	<i>The University of Hong Kong</i>
Sadahisa Ogasawara	<i>Chiba University</i>
Joong-Won Park	<i>Myongji Hospital</i>
Young Nyun Park	<i>Yonsei University</i>
Michiie Sakamoto	<i>International University of Health and Welfare</i>
Jinsil Seong	<i>Yonsei University</i>
YingHong Shi	<i>Department of Liver Surgery, Zhongshan Hospital, Fudan University</i>
Kyung-Suk Suh	<i>Seoul National University Hospital</i>
Hui-Chuan Sun	<i>Department of Liver Surgery, Zhongshan Hospital, Fudan University</i>
Han Chong Toh	<i>National Cancer Center Singapore</i>
Yingcheng Wu	<i>Fudan University</i>
Thomas Yau	<i>The University of Hong Kong</i>

Sheng-Long Ye	<i>Zhongshan Hospital, Fudan University</i>
Changhoon Yoo	<i>Asan Medical Center</i>
Su Jong Yu	<i>Seoul National University Hospital</i>
Man-Fung Yuen	<i>The University of Hong Kong/Department of Medicine</i>
Yongxiang Zhao	<i>Zhongshan Hospital, Fudan University</i>
Jian Zhou	<i>Zhongshan Hospital, Fudan University</i>

Australia

Amany Zekry	<i>UNSW Medicine & Health</i>
-------------	-----------------------------------

Canada

Sharlene Gill	<i>University of British Columbia</i>
---------------	---------------------------------------

Egypt

Ashraf Omar	<i>Cairo University</i>
-------------	-------------------------

Germany

Peter Galle	<i>Universitätsmedizin</i>
-------------	----------------------------

United States of America

Ghassan Abou-Alfa	<i>Memorial Sloan Kettering Cancer Center</i>
Vatche Agopian	<i>UCLA</i>
Hassan Azhari	<i>Memorial Sloan Kettering Cancer Center</i>
Xin Chen	<i>University of Hawai'i Cancer Center</i>
Christopher Crane	<i>Memorial Sloan Kettering Cancer Center</i>
Hashem El Serag	<i>Baylor College of Medicine</i>
Richard Finn	<i>UCLA</i>
John Gordan	<i>UCSF</i>
Tim Greten	<i>National Institutes of Health</i>
James Harding	<i>Memorial Sloan Kettering Cancer Center</i>
Brenda Hernandez	<i>University of Hawai'i Cancer Center</i>
William Jarnagin	<i>Memorial Sloan Kettering Cancer Center</i>
Riad Salem	<i>Northwestern University</i>
Lawrence Schwartz	<i>Memorial Sloan Kettering Cancer Center</i>
Amit Singal	<i>UT Southwestern</i>
Jiping Wang	<i>Brigham and Women's Hospital</i>
Alice Wei	<i>Memorial Sloan Kettering Cancer Center</i>
Linda Wong	<i>University of Hawai'i Cancer Center</i>
Hooman Yarmohammadi	<i>Memorial Sloan Kettering Cancer Center</i>

Disclosures and Conflict of Interest (COI) Mitigation

Faculty, Staff, and Planners' Disclosures

The following individuals have no relevant financial relationships with ineligible companies to disclose: Hassan Azhari, Ann-Lii, Xin Chen, Cheng, Tan To Cheung, Valerie Chew, Hashem El Serag, Tim Greten, Kwang-Hyub Han, James Harding, Etsuro Hatano, Brenda Hernandez, Yi-Hsiang Huang, William Jarnagin, Haeryoung Kim, Ming Kuang, Xiao Li, Lian-Xin Liu, Yasunori Minami, Irene Ng, Ashraf Omar, Young Nyun Park, Michiie Sakamoto, Jinsil Seong, YingHong Shi, Kyung-Suk Suh, Hui-Chuan Sun, Han Chong Toh, Jiping Wang, Yingcheng Wu, Thomas Yau, Sheng-Long Ye, Su Jong Yu, Amany Zekry, Yongxiang Zhao, Jian Zhou, and the staff of Physicians' Education Resource, LLC.

The following individuals have relevant financial relationships with ineligible companies to disclose*:

Faculty	Grant/Research Support	Consultant	Shareholder	Other
Ghassan Abou-Alfa	Agenus, Arcus, Astra Zeneca, BioN-tech, BMS, Elicio, Genentech/Roche, Helsinn, Parker Institute, Pertzye, Puma, QED, Servier, Yiviva	Abbvie, Alligator Astra Zeneca, Autem, Berry Genomics, BioNtech, Boehringer Ingelheim, BMS, Eisai, Exelixis, Genentech/Roche, Incyte, Ipsen, J-Pharma, Merck, Merus, Neogene, Novartis, Servier, Tango, Tempus, Vector, Yiviva		
Vatche Agopian		Early Dx, Inc., Eximius, Inc.		
Albert Chan				International Advisory Board: AstraZeneca
Stephen Chan	AstraZeneca, Eisai, Ipsen, MSD, Roche			
Christopher Crane	Elekta	Trisalis	Imusoft, Onctural	
Richard Finn		AstraZeneca, Bayer, BMS, CStone, Eisai, Genentech, Eli Lilly, Novartis, Pfizer, Roche		
Peter Galle				Advisory Boards: AstraZeneca, Bayer, BMS, Boston Scientific, Ipsen, Lilly, MSD, Roche
Sharlene Gill				Advisor/Advisory Board: AstraZeneca, BMS, Eisai, Roche
John Gordan				In Kind Support: eEFFECTOR, Mirati
Chih-Hung Hsu	To Institution: AstraZeneca, Merck Sharp & Dohme, NGM Biopharmaceuticals, Ono Pharmaceutical, Roche, Surface Oncology	Advisor: AstraZeneca, BMS, Ono Pharmaceutical; Roche		Honoraria: BMS, Eisai, Merck Sharp & Dohme, Ono Pharmaceutical, Roche
Masafumi Ikeda	To Institution: AstraZeneca, Bristol Myers Squibb, Bayer, Chugai, Eisai, MSD, Takeda	AbbVie, AstraZeneca, Chugai, Eisai, MSD		Honoraria: AbbVie, AstraZeneca, Chugai, Eisai, MSD, Takeda
Hyo-Cheol Kim				Honoraria: Guerbet, Sirtex Medical
Takahiro Kodama				Speaker: AstraZeneca, Chugai, Eisai
Norihiro Kokudo				Speaker: AstraZeneca
Masatoshi Kudo				Speaker: AstraZeneca, Chugai, Eisai
Masayuki Kurosaki				Speaker: AstraZeneca, Chugai, Eisai

Faculty	Grant/Research Support	Consultant	Shareholder	Other
Jeong Min Lee	Bayer, CMS, Gerbet, GE Healthcare, Starmed, RF Medical, Samsung Medison, Philips, Siemens			Honoraria: Bayer, Gerbet, GE Healthcare, Starmed, Samsung Medison, Philips
Sadahisa Ogasawara		AstraZeneca, Chugai-pharma, Eisai		Speaker: AstraZeneca, Chugai-pharma, Eisai, Eli Lilly, Takeda; Honoraria: AstraZeneca, Chugai-pharma, Eisai, Eli Lilly, Takeda
Joong-Won Park	AstraZeneca, BMS, Roche,	AstraZeneca, Beigene		Advisor: Roche; Honoraria: Eisai; Partnership: Genexin, Onconic, Utilex
Riad Salem		AstraZeneca, Boston Scientific, Cook Medical, Eisai, Genentech, Merck, Siemens		
Lawrence Schwartz				DSMB: BMS, Merck. Patent Beneficiary: Varian
Amit Singal		FujiFilm Medical Sciences, Exact Sciences, Abbott, Roche, Glycotest, GRAIL and Freenome, Bayer, Genentech, AstraZeneca, Eisai, Exelixis, Merck, Elevar, Boston Scientific, Sirtex, Histosonics		
Alice Wei				
Linda Wong				Speaker: AstraZeneca
Hooman Yarmohammadi	Guerbet LLC, SIR Foundation, Thompson Foundation			
Changhoon Yoo	Servier, Bayer, AstraZeneca, Ono Pharmaceuticals, Ipsen, Boryung Pharmaceuticals, Lunit Inc.			Honoraria: Servier, Bayer, AstraZeneca, Merck Sharp & Dompe, Eisai, Celgene, BMS, Ipsen, Novartis, Boryung Pharmaceuticals, Mundipharma, Rocher
Man-Fung Yuen	AbbVie, Arbutus Biopharma, Arrowhead Pharmaceuticals, Assembly Biosciences, Dicerna Pharmaceuticals, Fujirebio Incorporation, Gilead Sciences, Immunocore, Roche, Sysmex Corporation	AbbVie, Arbutus Biopharma, Arrowhead Pharmaceuticals, Assembly Biosciences, Dicerna Pharmaceuticals, Fujirebio Incorporation, Gilead Sciences, Immunocore, Roche, Sysmex Corporation, Aligos Therapeutics, AiCuris, Antios Therapeutics, Clear B Therapeutics, Finch Therapeutics, GlaxoSmithKline, Janssen, Tune Therapeutics, Vir Biotechnology		

PER[®] has identified and mitigated all COI prior to the start of this activity by using a multistep process.

**Information accurate at time of printing.*

Off-Label Disclosure and Disclaimer

This accredited CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing medical and/or nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to the diagnostic, treatment, and management options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any of the companies that provided commercial support for this activity.



Thank you for attending the **The 14th Asia-Pacific
Primary Liver Cancer Expert Meeting**

To register for upcoming accredited CE live activity
or to view our online accredited CE activities, please visit www.gotoper.com.

We appreciate your attendance and look forward to seeing you at future PER® accredited CE activities.

PROGRAM AT A GLANCE

FRIDAY, JULY 19

Locations

Hawaii Ballroom: Kauai & Maui

Hawaii Ballroom: Molokai

Honolulu Suite, Hawaii Ballroom: Lanai

DAY 1

Opening Ceremony

8:15 AM – 8:35 AM • Kaua'i Maui

State of the Art Lecture

8:45 AM – 9:15 AM • Kaua'i Maui

Moderator: Ghassan Abou-Alfa (US)

Speaker: Hashem El Serag (US)

State of the Art Lecture

8:45 AM – 9:15 AM • Moloka'i

Moderator: Kyung-Suk Suh (Korea)

Lawrence Schwartz (US)

Session 1a

APPLE-ILCA Joint Symposium: Pathogenesis and Surveillance of HCC

9:15 AM – 10:45 AM • Kaua'i Maui

Moderators: Stephan Chan (Hong Kong), Young Nyun Park (Korea)

Speakers: Amit Singal (US) Su Jong Yu (Korea) Haeryoung Kim (Korea)

Yi-Hsiang Huang (Taiwan)

Session 1b

Biologic Implications for Diagnosing and Treating Liver Cancer

9:15 AM – 10:45 AM • Moloka'i

Moderators: Kwang-Hyub Han (Korea), David Perry (New Zealand),

Michiie Sakamoto (Japan),

Speakers: Jeong-Min Lee (Korea) Masayuki Kurosaki (Japan)

Amany Zekry (Australia) Tan To Cheung (Hong Kong)

Coffee Break & Oral Poster Session

10:45 – 11:15 AM • Lana'i

Session 2a.

Locoregional Therapy East and West Debate of Modalities

11:15 AM – 12:55 PM • Kaua'i Maui

Moderators: Valerie Chew (Singapore), Jinsil Seong (Korea)

Speakers: Ming Kuang (China) Hooman Yarmohammadi (US)

Hyo Cheol Kim (Korea) Riad Salem (US) Chris Crane (US)

Jinsil Seong (Korea)

Session 2b.

Bridging IO With Ablation, Surgery, and Liver Transplant

11:15 AM – 12:55 PM • Moloka'i

Moderators: Sheng-Long Ye (China), Jian Zhou (China)

Speakers: Yasunori Minami (Japan) Linda Wong (US)

William Jarnagin (US) Ying-Hong Shi (China)

Lunch

12:55 PM – 2:10 PM • Hawaii Ballroom Foyer

Non-CE Product Theater: Navigating the Decision-Making in First-line Therapy for HCC: Insights from Various Clinical Indicators

12:55 PM – 2:10 PM • Honolulu Suite

Sponsored by Elevar Therapeutics

Speaker: Changhoon Yoo, MD, PhD (US)

Coffee Break & Oral Poster Session

2:10 PM – 2:24 PM • Lana'i

Presidential Lecture

2:40 PM – 3:10 PM • Kaua'i Maui

Moderators: Ghassan Abou-Alfa (US), Linda Wong (US)

Speaker: Norihiro Kokudo (Japan)

PROGRAM AT A GLANCE

FRIDAY, JULY 19

Locations

Hawaii Ballroom: Kauai & Maui

Hawaii Ballroom: Molokai

Honolulu Suite, Hawaii Ballroom: Lanai

Session 3.

Systemic Therapy for Advanced HCC

3:10 PM – 5:00 PM • Kaua'i Maui

Moderators: Xiao Li (China), Joong Won Park (Korea)

Speakers: Thomas Yau (Hong Kong) Hui-Chuan Sun (Shanghai) Masatoshi Kudo (Japan) Jiping Wang (US) Richard Finn (US)

General APPLE Association Meeting

5:00 PM – 6:00 PM • Kaua'i Maui

Welcome Luau Dinner

Ocean Lawn at the Royal Hawaiian Resort

6:30 PM – 8:30 PM

Engage with content and presenters in real-time!

STEPS TO CONNECT TO ARRAY

1

Connect to Wi-Fi.

a. Network:


MarriottBonvoy_Conference

b. Password:

APPLE2024

2

Scan the QR Code below.



3

If you do not have a QR Code Reader you can type the following URL into your web browser

gotoper.com/apple24-engage

PROGRAM AT A GLANCE

SATURDAY, JULY 20

Locations

Hawaii Ballroom: Kauai & Maui

Hawaii Ballroom: Molokai

Honolulu Suite, Hawaii Ballroom: Lanai

DAY 2

Breakfast

7:15 AM • Exhibit Hall

CME Breakfast Satellite Symposium: Medical Crossfire®: Individualizing Treatment Plans in Advanced Hepatocellular Carcinoma Based on Biology and Other Patient Characteristics

7:15 AM – 8:15 AM • Hawaii Ballroom: Moloka'i

Moderator: Ghassan Abou-Alfa (US)

Speakers: Richard Finn (US) Sharlene Gill (Canada) Masafumi Ikeda (Japan)

Session 4a.

Management of Hepatobiliary Cancer Outside of HCC and Other Topics

8:30 AM – 10:00 AM • Kaua'i Maui

Moderators: Stephen Chan (Hong Kong), Richard Finn (US)

Speakers: James J. Harding (US) John Gordan (US) Yingcheng Wu (China)
Peter Galle (Germany)

Session 4b.

Basic Science/Translational Research

8:30 AM – 10:00 AM • Moloka'i

Moderators: Irene Ng (Hong Kong), Changhoon Yoo (Korea)

Speakers: Yongxiang Zhao (China) Takahiro Kodama (Japan)
Xin Chen (US) Brenda Hernandez (US)

Coffee Break & Oral Poster Session

10:00 AM – 10:30 AM • Lana'i

State of the Art Lecture

10:30 AM – 11:00 AM • Kaua'i Maui

Moderator: Tim Greten (US)

Speaker: Jian Zhou (China)

Session 5a.

Surgery

11:10 AM – 12:40 AM • Kaua'i Maui

Moderators: Lian-Xin Liu (China), Alice Wei (US)

Speakers: Vatche Agopian (US) Alice Wei (US) Etsuro Hatano (Japan)
Albert Chan (Hong Kong)

Session 5b.

Hepatology in HCC Prevention and Management

11:10 AM – 12:40 AM • Moloka'i

Moderators: Sharlene Gill (Canada), Masafumi Ikeda (Japan)

Speakers: Hassan Azhari (US) Sadahisa Ogasawara (Japan)
Man-Fung Yuen (Hong Kong) Ashraf Omar (Egypt)

Lunch

12:40 PM – 1:55 PM • Hawaii Ballroom Foyer

OncoLive® Seminar: Advancements in the Management of Intermediate and Advanced Hepatocellular Carcinoma (HCC)

12:40 PM – 1:55 PM • Honolulu Suite

Speaker: Richard Finn (US)

Coffee Break & Oral Poster Session

1:55 PM – 2:25 PM • Lana'i

Session 6.

Future Directions for Molecular Classification and Management of HCC

2:25 PM – 3:55 PM • Kaua'i Maui

Moderators: Ghassan Abou-Alfa (US), Han Chong Toh (Singapore)

Speakers: Irene Ng (Hong Kong) Young Nyun Park (Korea) Ann-Lii Cheng (Taiwan) Masafumi Ikeda

Session 7.

Presentations of Selected Abstracts

3:55 PM – 5:05 PM • Kaua'i Maui

Moderators: Ghassan Abou-Alfa, Ann-Lii Cheng, Chih-Hung Hsu, Masatoshi Kudo, Linda Wong

Speakers: Claudia Foster (NZ) Shinji Itoh (Japan) Rohit Thummalapalli (US) Yingcheng Wu (China)

Closing Ceremony

5:05 PM – 5:30 PM • Kaua'i Maui

AGENDA

FRIDAY, JULY 19

General Session & Breakout Session A

Hawaii Ballroom: Kauai & Maui

Time	Title	Faculty
6:30 AM	Registration and Check-In	
7:00 AM	Breakfast in Exhibit Hall	
8:15 AM	Opening Ceremony	<i>Ghassan Abou-Alfa (US), Linda Wong (US)</i>
8:35 AM	Break between Opening Ceremony and State of the Art Lectures	
State of the Art Lecture 1.		<i>Moderator: Ghassan Abou-Alfa (US)</i>
8:45 AM	NASH Burden Worldwide Epidemiology and Global Burden of Liver Cancer	<i>Hashem El Serag (US)</i>
Session 1a. APPLE-ILCA Joint Symposium: Pathogenesis and Surveillance of HCC		<i>Moderators: Stephan Chan (Hong Kong), Young Nyun Park (Korea)</i>
9:15 AM	Abbreviated MRI and Novel Blood Work Modalities for HCC Surveillance	<i>Amit Singal (US)</i>
9:35 AM	cfDNA Methylation Signature for HCC Detection	<i>Su Jong Yu (Korea)</i>
9:55 AM	Biomarkers for Diagnosis and Prognostication of HCC: A Pathologist's Perspective	<i>Haeryoung Kim (Korea)</i>
10:15 AM	Management of Viral Hepatitis During HCC Treatment	<i>Yi-Hsiang Huang (Taiwan)</i>
10:35 AM	Discussion	
10:45 AM	Coffee Break & Oral Poster Session in Exhibit Hall	
Session 2a. Locoregional Therapy East and West Debate of Modalities		<i>Moderators: Valerie Chew (Singapore), Jinsil Seong (Korea)</i>
11:15 AM	TACE (15 minutes each, East vs West Perspective)	<i>Ming Kuang (China) Hooman Yarmohammadi (US)</i>
11:45 AM	TARE: Western Experience TARE: Korean Experience	<i>Hyo Cheol Kim (Korea) Riad Salem (US)</i>
12:15 PM	Radiation Therapy (15 minutes each, East vs West Perspective)	<i>Chris Crane (US) Jinsil Seong (Korea)</i>
12:45 PM	Discussion	
12:55 PM	Lunch in Hawaii Ballroom Foyer & Non-CE Product Theater: Navigating the Decision-Making in First-line Therapy for HCC: Insights from Various Clinical Indicators Located in the Honolulu Suite <i>Sponsored by Elevar Therapeutics</i>	<i>Changhoon Yoo, MD, PhD (US)</i>
2:10 PM	Oral Poster Session in Exhibit Hall	
Presidential Lecture		<i>Moderators: Ghassan Abou-Alfa (US), Linda Wong (US)</i>
2:40 PM	Borderline Resectable HCC: Role of Liver Resection in the Era of Advanced Systemic Therapy	<i>Norihiro Kokudo (Japan)</i>
Session 3. Systemic Therapy for Advanced HCC		<i>Moderators: Xiao Li (China), Joong Won Park (Korea)</i>
3:10 PM	Etiology-based Checkpoint Inhibitor Therapies	<i>Thomas Yau (Hong Kong)</i>
3:30 PM	Hepatectomy Following Conversion Therapy Using TKI/PD-1 in Unresectable HCC	<i>Hui-Chuan Sun (Shanghai)</i>
3:50 PM	Anti-Angiogenic Plus Checkpoint Inhibitor Systemic Therapy	<i>Masatoshi Kudo (Japan)</i>
4:10 PM	Systemic Therapy for Intermediate Stage Disease	<i>Jiping Wang (US)</i>
4:30 PM	Doublet Checkpoint Inhibition as Systemic Therapy	<i>Richard Finn (US)</i>
4:50 PM	Discussion	
6:30 PM	Welcome Luau Dinner on Ocean Lawn at the Royal Hawaiian Resort	

AGENDA (CONTINUED)

FRIDAY, JULY 19

General Session & Breakout Session A

Hawaii Ballroom: Kauai & Maui

Breakout Session B

Hawaii Ballroom: Molokai

Time	Title	Faculty
State of the Art Lecture 2.		<i>Moderator: Kyung-Suk Suh (Korea)</i>
8:45 AM	AI Applications in Liver Disease and Cancer	<i>Lawrence Schwartz (US)</i>
Session 1b. Biologic Implications for Diagnosing and Treating Liver Cancer		<i>Moderators: Kwang-Hyub Han (Korea), David Perry (New Zealand), Michiie Sakamoto (Japan)</i>
9:15 AM	Enhanced Ultrasound Techniques for HCC Diagnosis	<i>Jeong-Min Lee (Korea)</i>
9:35 AM	Use of AFP in Clinical Practice of Atezolizumab Plus Bevacizumab Therapy for uHCC	<i>Masayuki Kurosaki (Japan)</i>
9:55 AM	To Be Announced	<i>Amany Zekry (Australia)</i>
10:15 AM	Neoadjuvant vs Adjuvant Therapy: A Biological Approach	<i>Tan To Cheung (Hong Kong)</i>
10:35 AM	Discussion	
10:45 AM	Coffee Break & Oral Poster Session in Exhibit Hall	
Session 2b. Bridging IO With Ablation, Surgery, and Liver Transplant		<i>Moderators: Sheng-Long Ye (China), Jian Zhou (China)</i>
11:15 AM	Combining Local Ablation With Immunotherapy	<i>Yasunori Minami (Japan)</i>
11:35 AM	Bridging to Surgery Using Yttrium90	<i>Linda Wong (US)</i>
11:55 AM	Downstaging Conversion Therapy of uHCC After Systemic Therapy	<i>William Jarnagin (US)</i>
12:15 PM	Combination Downstaging Therapies in Liver Transplantation for Advanced HCC	<i>Ying-Hong Shi (China)</i>
12:35 PM	Discussion	
2:10 PM	Oral Poster Session in Exhibit Hall	

AGENDA

SATURDAY, JULY 20

General Session & Breakout Session A

Hawaii Ballroom: Kauai & Maui

Time	Title	Faculty
6:30 AM	Registration and Check-In	
7:15 AM	Breakfast in Exhibit Hall	
7:15 AM	CME Breakfast Satellite Symposium: Medical Crossfire: Individualizing Treatment Plans in Advanced Hepatocellular Carcinoma Based on Biology and Other Patient Characteristics Located in the Hawaii Ballroom: Molokai	<i>Moderator: Ghassan Abou-Alfa (US)</i> <i>Faculty: Richard Finn (US)</i> <i>Sharlene Gill (Canada)</i> <i>Masafumi Ikeda (Japan)</i>
8:15 AM	Break between Satellite and General Session	
Session 4a. Management of Hepatobiliary Cancer Outside of HCC and Other Topics		<i>Moderators : Stephen Chan (Hong Kong), Richard Finn (US)</i>
8:30 AM	Molecular Pathogenesis of Intrahepatic Cholangiocarcinoma	<i>James J. Harding (US)</i>
8:50 AM	Fibrolamellar Carcinoma	<i>John Gordan (US)</i>
9:10 AM	Immune Heterogeneity and Tumor-Immune Interactions in iCCA	<i>Yingcheng Wu (China)</i>
9:30 AM	Systemic Therapy for Biliary Cancers	<i>Peter Galle (Germany)</i>
9:50 AM	Discussion	
10:00 AM	Coffee Break & Oral Poster Session in Exhibit Hall	
State of the Art Lecture 3.		<i>Moderator: Tim Greten (US)</i>
10:30 AM	The Promotion and Application of the CNLC (ChiNa Liver Cancer) Guidelines for Hepatocellular Carcinoma	<i>Jian Zhou (China)</i>
11:00 AM	Break	
Session 5a. Surgery		<i>Moderators: Lian-Xin Liu (China), Alice Wei (US)</i>
11:10 AM	Predictors and Management of HCC Recurrence After Liver Transplant	<i>Vatche Agopian (US)</i>
11:30 AM	Robotic Surgery	<i>Alice Wei (US)</i>
11:50 AM	Living Donor Transplants for HCC	<i>Etsuro Hatano (Japan)</i>
12:10 PM	Surgery Versus Transplant Perspectives	<i>Albert Chan (Hong Kong)</i>
12:30 PM	Discussion	
12:40 PM	Lunch in Hawaii Ballroom Foyer & OnLive® Seminar: Advancements in the Management of Intermediate and Advanced Hepatocellular Carcinoma (HCC) Located in the in Honolulu Suite	<i>Richard Finn (US)</i>
1:55 PM	Oral Poster Session in Exhibit Hall	
Session 6. Future Directions for Molecular Classification and Management of HCC		<i>Moderators: Ghassan Abou-Alfa (US), Han Chong Toh (Singapore)</i>
2:25 PM	Looking Toward Molecular-Stratified Characterization of HCC	<i>Irene Ng (Hong Kong)</i>
2:45 PM	Update on Molecular and Pathological Features of Hepatobiliary Tumors	<i>Young Nyun Park (Korea)</i>
3:05 PM	What's Next for Adjuvant and Neoadjuvant Therapy for HCC?	<i>Ann-Lii Cheng (Taiwan)</i>
3:25 PM	Highlights in Early-Phase Clinical Trials for HCC Therapies	<i>Masafumi Ikeda (Japan)</i>
3:45 PM	Discussion	

AGENDA (CONTINUED)

SATURDAY, JULY 20

General Session & Breakout Session A

Hawaii Ballroom: Kauai & Maui

Session 7. Presentations of Selected Abstracts

Moderators: Ghassan Abou-Alfa, Ann-Lii Cheng, Chih-Hung Hsu, Masatoshi Kudo, Linda Wong,

3:55 PM Development of a Novel Prognostic Score for Intrahepatic Cholangiocarcinoma Based on Tumor Size and Number of Tumor *Chen Qing (China)*

4:10 PM Outcomes of Patients Receiving Lenvatinib or Atezolizumab Plus Bevacizumab as First-line Treatment for Unresectable Hepatocellular Carcinoma: PRISM Study *Shinji Itoh (Japan)*

4:25 PM Genomic Landscape of Clinically Actionable FGFR Alterations in Biliary Tract Cancer and Across Solid Tumors *Rohit Thummalapalli (US)*

4:40 PM Cancer Neutrophil Encyclopedia: A Deep Dive into Antigen-Presenting Warriors *Yingcheng Wu (China)*

4:55 PM Discussion

2024 Closing Ceremony

Moderators: Ghassan Abou-Alfa, Ann-Lii Cheng, Chih-Hung Hsu, Masatoshi Kudo, Linda Wong,

5:05 PM Summary of APPLE 2024/Closing Ceremony
APPLE 2025 Announcement *Ghassan Abou-Alfa (US), Linda Wong (US)*

Breakout Session B

Hawaii Ballroom: Molokai

Time	Title	Faculty
Session 4b. Basic Science /Translational Research		Moderators: Irene Ng (Hong Kong), Changhoon Yoo (Korea)
8:30 AM	New Technologies to Study Liver Cancer	<i>Yongxiang Zhao (China)</i>
8:50 AM	Biomarker Research of Combination Immunotherapy in HCC	<i>Takahiro Kodama (Japan)</i>
9:10 AM	AFP Vaccine and Novel Immune Checkpoint Inhibitors for HCC	<i>Xin Chen (US)</i>
9:30 AM	Cyanobacteria as a Risk Factor for HCC	<i>Brenda Hernandez (US)</i>
9:50 AM	Discussion	
10:00 AM	Coffee Break & Oral Poster Session in Exhibit Hall	
Session 5b. Hepatology in HCC Prevention and Management		Moderators: Sharlene Gill (Canada), Masafumi Ikeda (Japan)
11:10 AM	IO Treatment for Transplanted Patients	<i>Hassan Azhari (US)</i>
11:30 AM	Impact of Vascular Involvement on Treatment with Checkpoint Inhibitors	<i>Sadahisa Ogasawara (Japan)</i>
11:50 AM	How to Prevent HCC in Hepatitis B Disease	<i>Man-Fung Yuen (Hong Kong)</i>
12:10 PM	Treatment of Hepatitis B and C in Patients with HCC	<i>Ashraf Omar (Egypt)</i>
12:30 PM	Discussion	



Individualizing Treatment Plans in Advanced Hepatocellular Carcinoma Based on Biology and Other Patient Characteristics



Saturday, July 20, 2024

Faculty

Ghassan K. Abou-Alfa, MD, MBA
Richard Finn, MD
Sharlene Gill, MD, MPH, MBA, FRCP(C), FASCO
Masafumi Ikeda, MD

Overview

Management of advanced hepatocellular carcinoma (HCC) has continued to evolve as novel systemic therapy regimens continue to demonstrate benefits over classical single-agent treatment. With an expanding array of tools to tailor therapy to patient goals and characteristics, it is more difficult to identify optimal therapy for individual patients.

This discussion-based program is designed to provide key data updates on the management of advanced HCC, with an emphasis on incorporating current and emerging treatment regimens into individualized plans for patients. This will be presented in the context of clinical cases, illustrating difficult case scenarios that will allow the panel to provide their multinational expertise and perspectives.

Target Audience

This educational activity is directed toward physicians and other allied healthcare professionals involved in the diagnosis, treatment and management of hepatocellular carcinoma.

Learning Objectives

Upon completion of this activity, participants will be able to:

- Assess the efficacy and safety of current and emerging therapies and combinations for advanced/resectable hepatocellular carcinoma (HCC) in the frontline setting and beyond
- Develop personalized care plans for patients with advanced/metastatic HCC by integrating trial evidence, recent guidelines, tumor characteristics, patient comorbidities, and goals of therapy in the frontline setting and beyond
- Create proactive plans for monitoring and mitigating treatment-related adverse events associated with current and emerging therapies for patients with HCC

Slides/e-Syllabus

Final slides will be uploaded to the e-syllabus on the PER® website by 12:00 PM ET on Thursday, July 25, 2024. To access these materials, please visit <https://www.gotoper.com/asia-pacific-primary-liver-cancer-expert-meeting-advhcc-esyll>.

How to Request Credit

To complete the online evaluation and receive a certificate of credit or participation, please visit <https://www.gotoper.com/asia-pacific-primary-liver-cancer-expert-meeting-advhcc-eval>.

The online evaluation and the request for credit will be available beginning Sunday, July 21, 2024 and will remain available until Wednesday, September 4, 2024.

Accreditation/Designation of Credit

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgement of Educational Grant Support

This activity is supported by educational grants from Eisai, Inc and Merck Sharp, & Dohme Corp.


Faculty, Staff, and Planners' Disclosures

Please see disclosure information in the "Disclosure and Conflicts of Interest (COI) Mitigation" section of this workbook.

EXHIBITS

Lana'i Ballroom

EXHIBITOR	Booth Number
AbbVie	102
Abou-Alfa	109
Blue Faery	107
Eisai	103
Elevar	100
Exelixis	101
Genentech	105



Poster
Presentations

Breakfast and All Day
Beverages

ABSTRACT WINNERS

Development of a Novel Prognostic Score for Intrahepatic Cholangiocarcinoma Based on Tumor Size and Number of Tumor

Chen Qing

Outcomes of Patients Receiving Lenvatinib or Atezolizumab Plus Bevacizumab as First-line Treatment for Unresectable Hepatocellular Carcinoma: PRISM Study

Shinji Itoh

Cancer Neutrophil Encyclopedia: A Deep Dive into Antigen-Presenting Warriors

Yingcheng Wu

Genomic landscape of clinically actionable FGFR alterations in biliary tract cancer and across solid tumors

Rohit Thummalapalli

POSTERS

Location: Lana'i Ballroom

July 19, 2024 | 10:45 AM – 11:15 AM

1	Assessing Clinical Factors Influencing Deep Learning Performance in Organ Segmentation on Gadoxetic acid-enhanced MRI: A Retrospective Study of Chronic Liver Disease Patients	Na Yun Han	19	Comparison of Transarterial Chemoembolization vs Radioembolization for Large Unresectable Hepatocellular Carcinoma (> 8 cm): A Propensity Score Matching Analysis	Ho Jong Chun
2	Assessing Hepatic Metabolism in Patients with HCC Using 31P-MRS: Insights and Potential Clinical Utility	Yuchen Yang	20	First interim outcomes analysis of an investigator-initiated clinical trial evaluating liquid biopsy and PET-based predictive biomarkers for advanced unresectable hepatocellular carcinoma	Sandi Kwee
3	Multi-Channel Fluorescence Sensor Array for Protein Discrimination and its Application in Hepatocellular Carcinoma Diagnosis	Pan Wu	22	Immunoscore Predicted by Dynamic Contrast-enhanced Computed Tomography Can be a Non-invasive Biomarker for Immunotherapy of Hepatocellular Carcinoma	Eisuke Ueshima
5	Age difference in the association of alcohol consumption and the risk of hepatocellular carcinoma: A nationwide cohort study	Mi Na Kim	27	Predictive Imaging Features of Bile Duct Invasion in Hepatocellular Carcinoma on MRI with Hepatobiliary Contrast Agents	Jaeseung Shin
6	Fibrolamellar Carcinoma Registry: Opportunities and Challenges	Layal Al Mahmasani	29	Radiomics for Survival Risk Stratification of Multinodular Hepatocellular Carcinoma Patients Beyond the Milan Criteria	Xinyue Liang
7	Frequent AFP Testing Enhances Survival Rates in Hepatitis B-Associated Hepatocellular Carcinoma	Sang Bong Ahn	30	Real-world Application of Noncontrast-Abbreviated Magnetic Resonance Imaging in Hepatocellular Carcinoma Surveillance	Sunyoung Lee
10	A Machine Learning Model to Predict De Novo Hepatocellular Carcinoma Beyond Year 5 of Antiviral Therapy	Yeonjung Ha	38	Efficacy and safety of ablative radiotherapy for patients with primary liver cancers with massive inferior vena cava and cardiac extension	Carla Hajj
11	Changes in liver stiffness and controlled attenuation parameters of transient elastography according to weight change in non-alcoholic fatty liver disease	Seong Kyun Na	40	Feasibility Study of Combined Chemotherapy and Carbon-ion Radiotherapy for Hepatocellular Carcinoma Patients	Daijiro Kobayashi
13	Heavy Smoking Increases Early Mortality Risk in Patients with Hepatocellular Carcinoma after Curative Treatment	Soon Kyu Lee	42	Long-term outcome of a multicenter prospective study on efficacy and safety of high-dose Stereotactic Body Radiation Therapy ≥ 48 hour-interfraction interval for ≤ 5 cm hepatocellular carcinoma	Won Il Jang
14	Predictors of Normal Alpha-Feto Protein among Patients Who Underwent Surveillance for Hepatocellular Carcinoma	Tomoki Sempokuya	43	Preliminary Results of Sequential Transarterial Chemoembolization, Stereotactic Body Radiotherapy Followed by STRIDE in Unresectable Hepatocellular Carcinoma: Single-Arm Phase II Trial	Chi Leung Chiang
15	Similar recurrence after curative treatment of HBV-related HCC, regardless of HBV replication activity	Mi Na Kim	44	Radiotherapy for extrahepatic intraabdominal metastases from hepatocellular carcinoma	Sun Hyun Bae
16	A Comparative Analysis of RECIST 1.1 and mRECIST in Assessing Tumor Response to FOLFOX Regimen of Hepatocellular Carcinoma: Thailand Experience	Passakorn Wanchaijiraboon			

45	The Clinical Utilization of Radiotherapy for Liver and Gallbladder/Biliary Cancer in Republic of Korea between 2009 and 2020	Won Il Jang	68	Lenvatinib Versus Sorafenib as Second-Line Therapy Following Atezolizumab-Bevacizumab (Atezo-Bev) Failure in Unresectable Hepatocellular Carcinoma (uHCC): A Multicenter Retrospective Study from Korea and Japan	Changhoon Yoo
47	Survival Benefit of Resectability Determined by Multiple Surgeons in BCLC-C Stage: A Single-Center Cohort Study	Kyung Chul Yoon	69	No Correlation Between Proteinuria and Renal Function in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab + Bevacizumab: ARISE Study	Kazuomi Ueshima
167	Surgical strategy for incidental intrahepatic cholangiocarcinoma in terms of lymph node dissection	Sung Hyun Kim	70	Outcomes by Occurrence of Immune-mediated Adverse Events with Tremelimumab plus Durvalumab in the HIMALAYA Study in Unresectable Hepatocellular Carcinoma (uHCC)	Layal Al Mahmasani
183	Korean multicenter Prospective observational study on efficacy of Y90 for HCC (KURE-YTT-HCC): interim results	Dongho Hyun	71	Outcomes in the Asian Subgroup of the Phase 3 HIMALAYA Study of Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma (uHCC)	Joong-Won Park
July 19, 2024 2:10 PM – 2:40 PM					
48	Advances in Immunotherapy for Transplant Oncology	Maen Abdelrahim	72	PHF10 Splicing Isoform P/S Regulates Hepatocellular Carcinoma Progression through Mevalonate Pathway	xudong zhang
49	Clinical Features Of Patients Who Should Be Treated With Adjuvant Chemotherapy After Radiofrequency Therapy For Hepatocellular Carcinoma	Takuya Matsuda	74	Prognostic Factors for Survival Outcomes in Hepatocellular Carcinoma Patients Refractory to Transarterial Chemoembolization (TACE) and Treated with Hepatic Arterial Infusion Chemotherapy (HAIC)	Ho Jong Chun
54	Development of a Simple Predictive Method without Liver Stiffness for Significant Varices in Patients with Hepatocellular Carcinoma	Kana Matsuoka	75	Second-line Regorafenib in Patients with Unresectable Hepatocellular Carcinoma (uHCC) After Progression on Atezolizumab Plus Bevacizumab (Atezo-Bev): Final Results from the Phase 2 REGONEXT Trial	Changhoon Yoo
55	Diagnosis of HBV-associated liver cirrhosis and hepatocellular carcinoma by mass spectrometry-based high-throughput integrative serum lipidomics and peptidomics: A retrospective study	Xiao Liang	76	Second-line systematic strategy options for the progression of Lenvatinib plus Tislelizumab treating unresectable hepatocellular carcinoma: a retrospective study	Xiaozhun Huang
56	Donafenib Combined with Anti-PD-1 Antibody as Adjuvant Therapy for Patients with Hepatocellular Carcinoma at High Risk of Recurrence After Resection	XinXin Zeng	77	Synergistic targeting of ECM stiffness: integration of matrix softening and blocking of mechanical signal transduction in primary liver cancers	Xiao Liang
57	Efficacy of Postoperative Adjuvant Therapies in Patients with resected cholangiocarcinoma	Jung Wan Choe	80	The role of pgRNA in recurrence of advanced HCC after systematic therapy	Yifan Han
58	Evaluation of Patient-reported Outcomes (PROs) <65 or ≥ 65 Years Old (yo) from the CARES-310 Trial	Stephen L. Chan	81	The Safety of Immunotherapy in hematologic and solid organ transplant recipients: A retrospective analysis	Maen Abdelrahim
59	Examination of cases undergoing New FP therapy after resistance to Durvalumab+Tremelimumab therapy.	Akihiro Deguchi	83	Tumor burden incorporating AFP improves survival prediction for patients with HCC undergoing TACE: An international multicentre observational study	Guohong Han
60	Exposure-adjusted Incidence Rates of Adverse Events in the Phase 3 CARES 310 Trial of Camrelizumab plus Rivoceranib Compared to Sorafenib	Natalia Raphael	84	Utilization of Immunotherapy as a Neoadjuvant Therapy for Liver Transplant Recipients with Hepatocellular Carcinoma	Maen Abdelrahim
61	Gemcitabine-Based Therapy Versus Non-Gemcitabine-Based Therapy as Neoadjuvant for Liver Transplant Recipients with Cholangiocarcinoma: An Institution Experience	Maen Abdelrahim	85	New anti-cancer targets for regulatory T cells specific to integrin signaling	Caitlin Watumull
62	Hepatic Angiosarcoma Manifesting as Severe Thrombocytopenia	Arvin Jeremy Tan	88	Cadonilimab in Combination with Tyrosine Kinase Inhibitors as Second-line or Subsequent Treatment in Hepatocellular Carcinoma (HCC): A Retrospective Real-World Study	Zhenyu Lin
63	Impact of Baseline Liver Function on Survival Outcomes in the CARES-310 Trial	Arndt Vogel	89	Comparison of Atezolizumab Plus Bevacizumab Versus Multi-kinase Inhibitors in Patients With Transarterial Chemoembolization-refractory Unresectable HCC	Eun Jee Lim
64	Impact of Cynomorium syngaricum-4 talkh on Apoptosis in Ethanol-Induced Liver Inflammation	Badamsuren Dorjgotov			
65	Impact of Viral Etiology in the Phase 3 HIMALAYA Study of Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma (uHCC)	Guo-Ming Shi			
67	LEN-TACE for unresectable intermediate stage HCC: Association Between Survival and Duration of Complete Response in TACTICS-L	Kazuomi Ueshima			

90	Donafenib Combined with Anti-PD-1 Antibody and Interventional Surgery as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Retrospective Study	Qiuwen Ye
91	Durvalumab for anti-PD-1 refractory hepatocellular carcinoma	San-Chi Chen
92	Factors determining durable response in hepatocellular carcinoma treatment with atezolizumab and bevacizumab	Yutaka Yasui
93	Infiltrative morphology is associated with the immunosuppressive tumor microenvironment and poor clinical outcomes after atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma.	Sung Hwan Lee
94	Nivolumab (NIVO) and drug eluting bead transarterial chemoembolization (deb-TACE): Updated results from a phase 1 study of patients (pts) with liver limited hepatocellular carcinoma (HCC).	James Harding
96	Retreatment of Immune Checkpoint Inhibitors after Remission of Immune-related Adverse Events in Patients with Hepatocellular Carcinoma	Chih-Cheng Tan
97	The Efficacy and Safety of Atezolizumab and Bevacizumab Combination Therapy for Advanced Hepatocellular Carcinoma	Eunho Choi

July 20, 2024 | 10:00 AM – 10:30 AM

32	Beyond Selection Criteria: The Prognostic Impact of Macrotrabecular-Massive Hepatocellular Carcinoma in Liver Transplant	Eun-Ki Min
34	Idiopathic Vanishing Bile Duct Syndrome in a Young Female: A Case Report	Min Ji Kim
35	Preliminary study for the development of a deep learning model to recognize flapping tremors in patients with hepatic encephalopathy	Changhyeong Lee
36	To B or not to B – Reappraisal the Staging for Single Hepatocellular Carcinoma Larger than 5 cm	Chien-Hung Chen
99	A Tetraspan(in) Stabilizes Programmed Death-Ligand 1 during Hepatocellular Carcinoma Development	Wonsik Kim
101	Bile acid-mediated activation of hepatic stellate cells and myeloid cell leukemia-1 triggers hepatocarcinogenesis	Yuri Cho
102	BRAP regulates autophagy affecting the proliferation and metastasis of liver cancer cells	Hao Zhuang
104	Decreased NCOA5 expression promotes HCC Cell EMT and Metastasis via Transcriptional Derepression of ZEB1	Jun He
108	Integrative approaches about natural products to determine the antioxidant effects and its active compounds by systemical and biochemical analysis	Young Woo Kim
110	Oncogenic Roles of LAMC2 in Intrahepatic Cholangiocarcinoma via Promoting EGFR Translation	Junfang Ji
114	Tetraspan(in)-specific inhibitors blocked hepatic carcinogenesis via regulation of immune cell cytotoxicity	Soyeon Kim

118	Exosomal miRNA as a Useful Biomarker for Predicting the Response of Atezolizumab and Bevacizumab Therapy in Patients with Hepatocellular Carcinoma	Eunho Choi
121	Single-cell RNA sequencing reveals pro-inflammatory macrophages are essential for immune activation in hepatocellular carcinoma patients treated with immune	Yung-Yeh Su
122	Targeted next generation sequencing (NGS) of cell free (cf) DNA in biliary tract cancer (BTC)	James Harding
125	An Early Increase in IL-10 and TNF- α Levels Following Atezolizumab Plus Bevacizumab Treatment Predicts Survival in Advanced HCC Patients	Soon Kyu Lee
126	An Early On-Treatment HBeAg-Seroclearance Is Not Associated with A Low Risk of Hepatocellular Carcinoma and Decompensated Liver Cirrhosis: A Multicenter Study	Hyunjae Shin
127	Baseline FIB-4 may be a risk factor of recurrence after SBRT in patients with HBV-related small HCC	zhan zeng
128	Clinical Biomarker to Predict Efficacy of Nivolumab plus Ipilimumab in Advanced Hepatocellular Carcinoma after Failure of Prior Atezolizumab plus Bevacizumab therapy	Sangyoun Hwang
129	Distinct spatial distribution of tumor-associated neutrophil promotes hepatocellular carcinoma progression by regulating neutrophil extracellular traps	Chen Jiafeng
132	Body Mass Index as a Prelude to Hepatocellular Carcinoma and Metabolic Dysfunction associated Steatohepatitis Risk Factors in Patients with no Identified Risk Factor for Developing Hepatocellular Carcinoma	Layal Al Mahmasani
134	Significant male preference of TERT genetic alterations and HBV integration in young-age HBV-related HCC: implications for sex disparity	Hye Seon Kim
136	Sorted-Cell Sequencing on HCC Specimens Reveals EPS8L3 As a Key Player in Stemness Properties of CD24/CD13/EpCAM-Triple Positive HCC Cells	Yu Man Tsui
137	Tertiary Lymphoid Structure is a Prognostic Marker and Predict Immunotherapy Response in Combined Hepatocellular-Cholangiocarcinoma	Lu Chen
140	Direct-acting antiviral therapy for hepatitis C virus in patients with hepatocellular carcinoma: A nationwide cohort study	Teng-Yu Lee
142	HCC risk factor after sustained virologic response of chronic hepatitis C related cirrhosis patients treated with Direct-acting antiviral treatment	Jeong Han Kim
144	Incidence and Risk of Controlled Attenuation Parameter-Based Non-alcoholic Hepatosteatosis Development in Korean Patients with Chronic Hepatitis B	Ye Rin Chae

July 20, 2024 | 1:55 PM – 2:25 PM

138	Differential HBV replicative markers and covalently closed circular DNA transcription in immune-active chronic hepatitis B with and without HBeAg	Hye Seon Kim
-----	---	--------------

145	The effect of HBV-DNA change on tumor recurrence in resected HBV-HCC patients: A multi-center study	Tae Yoo	171	Clinical Significance of Hepatectomy for Hepatocellular Carcinoma Associated with Lymph Node and/or Distant Metastases	Kenji Fukushima
149	Comparison of surgical and long-term outcomes after liver resection in patients with NAFLD-HCC versus HBV-HCC: A multicenter matched analysis	Na Reum Kim	172	Effects of Neoadjuvant Therapy on Mortality and Hospital Stay after Hepatectomy for Cancer	Akin Erol
150	Concurrent Usage of Antibiotics with Anti-PD-1 Antibody Associated with Reduced Anti-tumor Efficacy in Advanced Biliary Tract Cancer	Chaochen Zhang	173	Initial Experience with Single Port Robotic Liver Resection using the da Vinci SP System: A Case Series	Kwangpyo Hong
151	Do low skeletal muscle mass and disturbed body fat volume have survival impact on stage I/II HCC patients undergoing hepatectomy?	Chao-Wei Lee	174	Laparoscopic Liver Resection after Pancreaticoduodenectomy	Masahiro Kido
152	Efficacy and safety of donafenib combined with TACE for postoperative adjuvant therapy in patients with high risk of recurrence of hepatocellular carcinoma: a retrospective analysis	Binwei Duan	175	Liver Transplantation for Far Advanced Hepatocellular Carcinoma with Major Vascular Involvement: A Case	Geun Hong
153	Efficacy and safety of yttrium-90 transarterial radioembolization for intermediate- and advanced-stage hepatocellular carcinoma	Keren Li	178	Carbon-ion radiotherapy for hepatocellular carcinoma: A nationwide multicenter registry analysis by Japan carbon-ion radiation oncology study group (J-CROS)	Kei Shibuya
154	Efficacy of Yttrium90 Transarterial Radioembolization as a Bridge to Surgery	Amelia Wong	179	Clinical Outcome of Hepatocellular Carcinoma after Radiofrequency Ablation According to Distance Between Liver Surface and Hilum	Gwang Hyeon Choi
155	Fluorescence-guided Laparoscopic Portal Vein Basin Hepatectomy via Indocyanine Green Injected into the Main Portal Vein: A Single-center Experience	Ai Shen	180	Combination of SBRT with Yttrium-90:Case Series about the Safety and Efficacy for PHC with PVT	Hui Zhang
156	Health Economics Study of Robots and Laparoscopy liver resection for Hepatocellular Carcinoma	Xiao Liang	181	Difference in the development of acute kidney injury by chemotherapeutic agents in patients with hepatocellular carcinoma undergoing transarterial chemoembolization	Byung IK Kim
160	Predictors of micrometastases in patients with Barcelona Clinic Liver Cancer classification B hepatocellular carcinoma	Yoo Shin Choi	184	Position of Hepatic Arterial Infusion Chemotherapy in the treatment of HCC	Shuntaro Obi
161	Propensity Score-Matched Study on the Benefit of Conversion Therapy in Hepatocellular Carcinoma Treatment	Ruyu Han	185	Safety of Radiofrequency Ablation for Hepatocellular Carcinoma in Patients after Endoscopic Papillary Balloon Dilation	Makoto Moriyama
162	Resectability as a Prognostic Indicator in BCLC Stage B Hepatocellular Carcinoma: Challenging Current Treatment Paradigms	YoungRok Choi	186	The Efficacy and Safety of Selective Internal Radiation Therapy in Large Unresectable Hepatocellular Carcinoma: the First Experience in Chinese Patients	Leyang Xiang
165	Short-term Outcomes of Indocyanine Green Fluorescence-guided Anterior Approach for Laparoscopic Right Hemihepatectomy in the Treatment of Hepatocellular Carcinoma	Ai Shen	188	Transarterial Radioembolization versus Atezolizumab plus Bevacizumab in Hepatocellular Carcinoma with Portal Vein Thrombosis	Youngsu Park
166	Surgical and long-term outcome between Open and minimally invasive liver resection for multiple hepatocellular carcinoma : A propensity-score matched analysis	Na Reum Kim	189	Unveiling Real-World Insights on the Vital Role of Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma Patients	Imelda Loho
168	Textbook outcomes in initial liver resection for hepatocellular carcinoma: a study with malnutrition grade by the GLIM criteria.	Kentaro Oji			

NOTES

[illegible]

NOTES

This image shows a single sheet of white paper with horizontal ruling lines. The lines are evenly spaced and run across the width of the page. There are no margins, text, or other markings on the paper.

NOTES

[illegible]

APPLE 2025

The 15th Asia-Pacific Primary Liver Cancer Expert Meeting

■ Date

July 11 (Fri.) – 13 (Sun.), 2025

■ Venue

Kobe Portopia Hotel

■ Hosting Chairperson

Takumi Fukumoto

Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery,
Kobe University Graduate School of Medicine

Secretariat: Convention Linkage, Inc.
PIAS TOWER 11F, 3-19-3 Toyosaki, Kita-ku, Osaka 531-0072, Japan
TEL: +81-6-6377-2188 FAX: +81-6-6377-2075 E-mail: apple2025@c-linkage.co.jp

<https://www.c-linkage.co.jp/apple2025/>

